| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11263933 | Cancer Treatment Reviews | 2018 | 7 Pages |
Abstract
This meta-analysis provides further evidence in favor of BT boost for intermediate and high-risk prostate cancer in terms of b-PFS improvement, leading to suggest BT boost as level I and grade A recommendation. However, the risk of gradeâ¯â¥â¯3 late toxicity must be carefully investigated.
Keywords
ADTTOIHDRAMSTARQOLPRISMARCTsLDREBRTNCCNQuality of lifeRandomized controlled trialsPreferred Reporting Items for Systematic reviews and Meta-analysisConsolidated Standards of Reporting TrialsBrachytherapyBEDBiochemical progression-free survivaloverall survivalRelative riskGrade 3androgen deprivation therapyBiological effective doseNational Comprehensive Cancer Networkconfidence intervalHigh-dose rateLow-dose ratehazard ratioExternal beam radiotherapyCONSORTgastro-intestinal
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Daniel Lam Cham Kee, Jocelyn Gal, Alexander T. Falk, Renaud Schiappa, Marie-Eve Chand, Mathieu Gautier, Jérôme Doyen, Jean-Michel Hannoun-levi,